Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine

被引:40
|
作者
Edelman, KJ [1 ]
He, QS
Makinen, JP
Haanpera, MS
Minh, NNT
Schuerman, L
Wolter, J
Mertsola, JA
机构
[1] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland
[2] Natl Publ Hlth Inst, Dept Human Microbial Ecol & Inflammat, Turku, Finland
[3] GlaxoSmithKline Biol, Rixensart, Belgium
关键词
D O I
10.1086/421943
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We evaluated pertussis-specific cell-mediated immunity (CMI) and humoral immunity in adolescents 3 years after they received an acellular pertussis booster immunization. Two hundred sixty-four adolescents were examined for immunoglobulin G antibodies, and 49 were examined for CMI against Bordetella pertussis antigens 40 months after receiving the booster. A control group of similarly aged adolescents who had received diphtheria and tetanus vaccination 3 years earlier was included for comparison. Pertussis-specific CMI persisted at greater than prebooster immunization levels. Although they had decreased by the 3-year follow-up, antibody levels remained significantly higher than prebooster immunization levels. Antibodies against pertussis antigens and CMI against filamentous hemagglutinin and pertactin were significantly higher in vaccinated adolescents than in control subjects. The acellular pertussis booster immunization provides long-term CMI and humoral immunity lasting for greater than or equal to3 years. The significantly higher immunity observed in the diphtheria, tetanus, and acellular pertussis vaccine recipients, compared with that in control subjects, indicates that these responses are more likely to have resulted from the booster immunization than from the boosting effects of natural B. pertussis infection.
引用
下载
收藏
页码:179 / 185
页数:7
相关论文
共 50 条
  • [41] Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines
    Pitisuttithum, Punnee
    Dhitavat, Jittima
    Sirivichayakul, Chukiat
    Pitisuthitham, Arom
    Sabmee, Yupa
    Chinwangso, Pailinrut
    Kerdsomboon, Chawanee
    Fortuna, Librada
    Spiegel, Jane
    Chauhan, Mukesh
    Poredi, Indrajeet Kumar
    van den Biggelaar, Anita H. J.
    Wijagkanalan, Wassana
    Viviani, Simonetta
    Mansouri, Souad
    Pham, Hong Thai
    ECLINICALMEDICINE, 2021, 37
  • [42] Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology
    Sheridan, Sarah L.
    Frith, Katie
    Snelling, Thomas L.
    Grimwood, Keith
    McIntyre, Peter B.
    Lambert, Stephen B.
    EXPERT REVIEW OF VACCINES, 2014, 13 (09) : 1081 - 1106
  • [43] Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis
    Giuliano, M
    Mastrantonio, P
    Giammanco, A
    Piscitelli, A
    Salmaso, S
    Wassilak, SGF
    JOURNAL OF PEDIATRICS, 1998, 132 (06): : 983 - 988
  • [44] COMPARISON OF ACELLULAR PERTUSSIS-VACCINE WITH WHOLE CELL VACCINE AS A BOOSTER IN CHILDREN 15 TO 18 MONTHS AND 4 TO 6 YEARS OF AGE
    BERNSTEIN, DI
    SMITH, VE
    SCHIFF, GM
    RATHFON, HM
    BOSCIA, JA
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (02) : 131 - 135
  • [45] ACELLULAR PERTUSSIS-VACCINE - IMMUNOGENICITY AND SAFETY OF AN ACELLULAR PERTUSSIS VS A WHOLE CELL PERTUSSIS-VACCINE COMBINED WITH DIPHTHERIA AND TETANUS TOXOIDS AS A BOOSTER IN 18-MONTH TO 24-MONTH OLD CHILDREN
    PICHICHERO, ME
    BADGETT, JT
    RODGERS, GC
    MCLINN, S
    TREVINOSCATTERDAY, B
    NELSON, JD
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (04) : 352 - 363
  • [46] Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants
    Esposito, S
    Faldella, G
    Giammanco, A
    Bosis, S
    Friscia, O
    Clerici, M
    Principi, N
    VACCINE, 2002, 20 (23-24) : 2928 - 2932
  • [47] BscF from Bordetella pertussis provides advantageous adjuvant activity when paired with the acellular pertussis vaccine: enhanced Th1/Th17 pertussis-specific immune response
    Alvine, Travis D.
    Knopick, Peter L.
    Kumar, Meera Ajeet
    Nilles, Matthew L.
    Bradley, David S.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [48] Intranasal Immunization With a c-di-GMP-Adjuvanted Acellular Pertussis Vaccine Provides Superior Immunity Against Bordetella pertussis in a Mouse Model
    Jiang, Wenwen
    Wang, Xiaoyu
    Su, Yuhao
    Cai, Lukui
    Li, Jingyan
    Liang, Jiangli
    Gu, Qin
    Sun, Mingbo
    Shi, Li
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [49] Half-life Estimation of Pertussis-Specific Maternal Antibodies in (Pre)Term Infants After In-Pregnancy Tetanus, Diphtheria, Acellular Pertussis Vaccination
    Embacher, Stefan
    Maertens, Kirsten
    Herzog, Sereina A.
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (11): : 1640 - 1648
  • [50] Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age
    Vergara, R
    Tregnaghi, M
    Ussher, J
    Navarro, S
    Rüttimann, R
    Potin, M
    Wolter, J
    Schuerman, L
    EUROPEAN JOURNAL OF PEDIATRICS, 2005, 164 (06) : 377 - 382